Snowball logo
logo
RGEN_logo

Repligen Corporation

RGEN โ€ข NASDAQ
$172.91-$1.82ย  (1.04%)
Estimate
P/E
233.7
EPS
0.74
Beta
1.012
Growth
Revenue, YoY
11.93%
Net income, YoY
-66.31%
FCF, YoY
31.73%
Forecast
P/E (FWD)
65.5
EPS (FWD)
2.639
About the company
Ticker
RGEN
ISIN
US7599161095
Country
United States of America
Sector (GICS)
Healthcare
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

What sector does Repligen Corporation (RGEN) operate in?

Repligen Corporation belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is Repligen Corporation (RGEN) current stock price?

As of the latest data, Repligen Corporation stock price is $172.91, with a previous close of $174.73. Repligen Corporation lost -$1.82 in the last trading session, representing a -1.04% loss.

What is Repligen Corporation (RGEN) current market capitalization?

Repligen Corporation market cap is approximately 9.76 billion.

What is Repligen Corporation (RGEN) Earnings Per Share (EPS)?

The trailing EPS is $0.74, and the forward EPS is $2.64.

What is Repligen Corporation (RGEN) Price-to-Earnings (P/E) ratio?

Repligen Corporation current P/E ratio is 233.66, with a forward P/E of 65.52.

What is Repligen Corporation (RGEN) EBITDA?

Repligen Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.39 million.

Does Repligen Corporation (RGEN) pay dividends?

No. Repligen Corporation does not pay a dividend.

How did Repligen Corporation (RGEN) perform in its most recent earnings report?

In the last report (June 30, 2026), Repligen Corporation posted an EPS surprise of 20% and a revenue surprise of 1.35%.

What is Repligen Corporation (RGEN) beta (volatility) score?

Repligen Corporation has a beta of 1.012, meaning its volatility is roughly in line with the market.